BMY•benzinga•
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Summary
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 21, 2025 by benzinga